Tissue Regenix Group (TRX)

 

TRX Share PerformanceMore

52 week high22.000 31/05/16
52 week low15.000 20/04/17
52 week change -4.500 (-22.22%)
4 week volume2,138,123 31/03/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Tissue Regenix issues equity

Tissue Regenix Group has today issued and allotted about 1.3m shares of 0.5p each, following an exercise of options which w...

Issue of Equity

RNS Number: 2415B Tissue Regenix Group PLC 03 April 2017 Tissue Regenix Group Plc Issue of equity and total voting rights Leeds, 3 April 2017 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Company"), the regenerative medical devices company,announces that it has today issued and allotted 1,295,632 ordinary shares of 0.5p each in the Company, ...

Hardman Research: Addressing woundcare in the US

RNS Number: 1719Z Tissue Regenix Group PLC 13 March 2017 Hardman Research: Addressing woundcare in the US Addressing woundcare in the US: TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine tissues for the wound care, orthopaedics, and cardiac markets. Sales of DermaPure have continued to ga...

Innovative Technology Contract Awarded

RNS Number: 1394Y Tissue Regenix Group PLC 01 March 2017 Tissue Regenix Group plc Innovative Technology Contract Awarded DermaPure Receives Innovative Technology Contract from Vizient, Inc. Leeds, 01 March 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group"), the regenerative medical devices company, announces effective from...

TRX says DermaPure added to Federal Supply Schedule

Tissue Regenix Group has been included on the US Department of Veteran Affairs (VA) Federal Supply Schedule (FSS) vi...

DermaPure? added to the Federal Supply Schedule

RNS Number: 8102V Tissue Regenix Group PLC 02 February 2017 Tissue Regenix Group plc DermaPure added to the Federal Supply Schedule Leeds, 02 February 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today announces DermaPure a decellularized dermal allograft, utilising Tissue Regen...

Tissue Regenix appoints Paul Devlin as group FD

Tissue Regenix Group announces the appointment of Paul Devlin as Group Finance Director and Company Secretary with...

Directorate Change

RNS Number: 4867T Tissue Regenix Group PLC 06 January 2017 Tissue Regenix Group plc Appointment of Group Finance Director Leeds, 06 January 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today announce the appointment of Paul Devlin as Group Finance Director and Company Secret...

Fundamental DataMore

EPS-1.27
Dividend yield0 %

Equity Research (TRX)

hardman & co
Tissue Regenix Group Plc
17/03/2017
TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine tissues for the wound care, orthopaedics, and cardiac markets. Sales of DermaPure have...
edison investment research
Tissue Regenix Group Plc
03/02/2017
Edison Investment Research is terminating coverage on Tissue Regenix Group (TRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should...
edison investment research
Tissue Regenix Group Plc
19/10/2016
Tissue Regenix’s interim results are in line with our expectations and demonstrate the progress the company is making to achieve various milestones in each of its divisions. In particular, its Wound...

Latest discussion posts More

  • Re: RNS Hardman Research

    Yes, CL, it looks like a few others have taken the same view, hence the recent weakness in the sp. I'm holding for now, and may buy more if it drops further. The ...
    20-Mar-2017
    theprior
  • Re: RNS Hardman Research

    Thought this was a positive note on where TRX is now. Lots of pluses. I was bit thrown by the lack of near future potential profit or move into profit from all the increase in ...
    13-Mar-2017
    Chicken Lips
  • RNS Hardman Research

    Interesting to note wider expansion of product availability across different sectors and projections of future ...
    13-Mar-2017
    theprior

Users' HoldingsMore

Users who hold Tissue Regenix Group also hold..
LLOYDS GRP.32%
BP23%
TESCO22%
SIRIUS MINERALS20%
CENTRICA16%

Codes & Symbols

ISINGB00B5SGVL29
SymbolsTRX, LSE:TRX, TRX.L, TRX:LN, LON:TRX, XLON:TRX